glp 1 drugs for insulin resistance GLP−1 receptor agonists the treatment of obesity: Role as a promising approach GLP-1 for Prevention: Using Drugs

As of 2024, three GLP1 agonists have been approved for weight loss

For people with T2D, survodutide 1.8 mg twice weekly resulted in 9% WL vs

Weight reduction can be achieved through dietary and exercise modifications, and both are recommended by the American Heart Association(AHA)/American College of Cardiology (ACC) and European Society of Cardiologys (ESC) current guidelines, due to their lasting impacts on lipid profiles [19, 27, 28]

Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, et al

This leads to less fat being absorbed and more energy being burned, which may explain part of GLP-1s effectiveness in supporting weight management (Singh et al, 2024)

Finding the right balance within the population of dual or triple agonists in development is going to be one of the toughest challenges